Ziopharm Oncology Inc., Investment Losses
The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended Ziopharm Oncology Inc., to investors.
ZIOPHARM Oncology, Inc., a biopharmaceutical company based in Boston, MA, reportedly engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer.
According to MarketWatch, as of November 15, 2020, the share price of Ziopharm Oncology Inc. has dropped more than -40% in the past year.
The problem with pharmaceutical and biotech investments such as Ziopharm Oncology, Inc., is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.